Investigational drug · Phase 3
Safusidenib
Also called: DS-1001b, AB-218
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Oligodendroglioma, Glioma, IDH1-mutant Glioma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "Safusidenib"
First trial start
2020
Jul 8, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Safusidenib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Oligodendroglioma
- Glioma
- IDH1-mutant Glioma
- Astrocytoma IDH Mutant Grade 2
- Astrocytoma, Grade IV
- Astrocytoma, IDH-Mutant, Grade 3
- Astrocytoma, IDH-Mutant, Grade 4
- Astrocytoma, IDH-Mutant, Grade 2
- Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
- Grade 2 IDH1-mutant Glioma
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Safusidenib" as an intervention, largest first.
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Pivotal-lookingRecruiting
Nuvation Bio Inc.Industry
NCT05303519 · 365 participants (planned) · Start Jun 5, 2023 · Primary completion Dec 1, 2028
Drug: safusidenib; Placebo · For: Glioma; Astrocytoma, Grade IV; IDH1-mutant Glioma and 5 more
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 75 sites in all
- Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant GliomaPivotal-lookingNot yet recruiting
Nuvation Bio Inc.Industry
NCT07712757 · 140 participants (planned) · Start Mar 2027 · Primary completion May 2029
Drug: Safusidenib; Placebo · For: Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation; Astrocytoma IDH Mutant Grade 2; Oligodendroglioma and 2 more
Nuvation Bio Inc.Industry
NCT07703436 · 40 participants (planned) · Start Mar 2027 · Primary completion Sep 2030
Drug: Safusidenib · For: Grade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma; Glioma and 5 more
Sites: Los Angeles, California; San Francisco, California; New Haven, Connecticut · 12 sites in all
- Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II StudyNot yet recruiting
University of ZurichAcademic, hospital or other
NCT07832123 · 20 participants (planned) · Start Mar 2027 · Primary completion Mar 2029
Drug: Safusidenib · For: Glioma : Oligodendroglioma or Astrocytoma
Sites: Zurich, Switzerland
Melbourne HealthAcademic, hospital or other
NCT05577416 · 14 participants · Start Oct 11, 2022 · Primary completion Mar 26, 2025
Drug: Part A: Safusidenib Erbumine; Part B: Safusidenib Erbumine · For: Glioma
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.
Arakawa Y, Saito R, Kanemura Y, et al. · Neuro Oncol 2026
- Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.
Fujimoto K, Honda-Kitahara M, Hattori N, et al. · Acta Neuropathol 2026
- Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.
Drummond KJ, Spiteri M, Cain SA, et al. · Nat Med 2025
- Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review.
Lanman TA, Gonzalez Castro LN · Cancers (Basel) 2025
- Establishment and characterization of TK-DDCS1: a novel IDH1 mutated dedifferentiated chondrosarcoma cell line.
Saisuwan K, Boonnate P, Goto H, et al. · Hum Cell 2025
- A perioperative study of Safusidenib in patients with IDH1-mutated glioma.
Cain SA, Topp M, Rosenthal M, et al. · Future Oncol 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.